1.50432

LiChrosorb^® RP-8 (5 µm) HPLC Columns

L x I.D. 125 mm x 4 mm, Hibar^® RT HPLC Column

• Synonym(e): TM=["LiChrosorb"] C8 HPLC column
• UNSPSC-Code: 41115709
• NACRES: SB.52

Eigenschaften

• product name: LiChrosorb^® RP-8 (5 µm) Hibar^® RT 125-4, suitable for HPLC
• Materialien: stainless steel column
• Qualitätsniveau: 100
• Agentur: suitable for USP L7
• Produktlinie: LiChrosorb^®
• Leistungsmerkmale: endcapped: no
• Parameter: 400 bar pressure; 60 °C max. temp.
• Methode(n): HPLC: suitable; mass spectrometry (MS): suitable (Low)
• Säule L × ID: 12.5 cm × 4 mm
• Matrix: fully porous particle
• Aktive Matrixgruppe: C8 bonding phase
• Partikelgröße: 5 μm
• Porengröße: 100 Å pore size
• operating pH range: 2-7.5
• Trenntechnik: reversed phase; supercritical fluid (SFC)
• Lagertemp.: no temp limit

Beschreibung

Allgemeine Beschreibung

HPLC column

LiChrosorb^® RP-8 is a reliable irregular shaped silica gel carriers with reversed phase properties. It is well suited for the separation of neutral, acidic and weak basic compounds.This sorbent is packed into a Hibar 125-4 HPLC column. For mounting of a LiChroCART 4-4 guard column, the guard column holder 1.51487 has to be used.

Anwendung

• Determination of amphotericin B, liposomal amphotericin B, and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatography.: This study by Egger et al. focuses on the HPLC determination of various forms of amphotericin B in plasma, utilizing LiChrosorb^® RP-8 as the stationary phase. This method ensures accurate monitoring of these antifungal agents in clinical settings (Egger et al., 2001).


• Determination of peptide hydrophobicity parameters by reversed-phase high-performance liquid chromatography.: This research by Rothemund et al. used LiChrosorb^® RP-8 to determine the hydrophobicity of various peptides, providing valuable insights for peptide characterization in biochemical research (Rothemund et al., 1994).


• HPLC determination of doxorubicin, doxorubicinol and four aglycone metabolites in plasma of AIDS patients.: Beijnen et al. employed LiChrosorb^® RP-8 in an HPLC method to quantify doxorubicin and its metabolites in plasma, offering a robust tool for therapeutic drug monitoring in AIDS patients (Beijnen et al., 1991).

Hinweis zur Analyse

Druck: ≤ 50 bar
Theoretische Bodenzahl (N/m) (Toluol): ≥ 55000
Symmetrie (Toluol): 0.8 - 1.4
Kapazitätsfaktor (Toluol): 0.5 - 1.5

Rechtliche Hinweise

Hibar is a registered trademark of Merck KGaA, Darmstadt, Germany

LiChrosorb is a registered trademark of Merck KGaA, Darmstadt, Germany